Cargando…

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

Chronic myeloproliferative neoplasms (MPN) frequently evolve to a blast phase (BP) that is almost uniformly resistant to induction chemotherapy or hypomethylating agents. We explored the functional properties, genomic architecture, and cell of origin of MPN-BP initiating cells (IC) using a serial NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoli, Rampal, Raajit K., Hu, Cing Siang, Tripodi, Joseph, Farnoud, Noushin, Petersen, Bruce, Rossi, Michael R., Patel, Minal, McGovern, Erin, Najfeld, Vesna, Iancu-Rubin, Camelia, Lu, Min, Davis, Andrew, Kremyanskaya, Marina, Weinberg, Rona Singer, Mascarenhas, John, Hoffman, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089790/ https://www.ncbi.nlm.nih.gov/pubmed/35259128 http://dx.doi.org/10.1172/jci.insight.156534

Ejemplares similares

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
por: Tripodi, Joseph, et al.
Publicado: (2010)

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
por: Ajufo, Helen O., et al.
Publicado: (2023)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
por: Mascarenhas, J, et al.
Publicado: (2019)

PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
por: Hanna, Matthew G., et al.
Publicado: (2015)

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
por: Mughal, Tariq I., et al.
Publicado: (2020)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Role of Interfacial Conditions on Blast Overpressure Propagation Into the Brain
por: Chen, YungChia, et al.
Publicado: (2020)

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
por: Zaroogian, Zachary, et al.
Publicado: (2023)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells
por: Saleiro, Diana, et al.
Publicado: (2023)

Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
por: Kozak, Kathryn E., et al.
Publicado: (2021)

Chromothripsis in lipoblastoma: second reported case with complex PLAG1 rearrangement
por: Lanceta, Joel, et al.
Publicado: (2023)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
por: Saleiro, Diana, et al.
Publicado: (2022)

MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report
por: He, Zhipeng, et al.
Publicado: (2018)

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
por: Mascarenhas, John, et al.
Publicado: (2011)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

The law of blast stress wave propagation and fracture development in soft and hard composite rock
por: Ding, Xiaohua, et al.
Publicado: (2022)

Acute myocardial infarction in myeloproliferative neoplasms
por: Manan, Muhammad Romail, et al.
Publicado: (2023)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

Cracks propagation characteristics of double-hole delay blasting in soft-hard composite rock mass
por: Cui, Jianbin, et al.
Publicado: (2023)

The Emergence and Challenging Growth of the Bio-Ethanol Innovation System in Taiwan (1949–2015)
por: Chung, Chao-Chen, et al.
Publicado: (2016)

Double minute amplification of mutant PDGF receptor α in a mouse glioma model
por: Zou, Hongyan, et al.
Publicado: (2015)

Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma
por: Sivendran, Shanthi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vre20pmc70v1u2rspvk805hdn1